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formed independently and relative risk (RR) estimates were calculated from each
study. To determine the relationship between inhaled anticholinergics and mor-
tality, datawere pooled using the randomeffectsmodel (inverse variancemethod).
Between-study heterogeneity was assessed using the I2-statistic. RESULTS: Of the
684 citations reviewed, a total of 18 RCTs enrolling more than 33,000 patients met
the inclusion criteria. Inhaled anticholinergics were not associated with an in-
creased risk of all-causemortality [RR1.10 (95%CI: 0.88,1.36), I236%]. Tiotropium
only group showed similar results. Subgroup analyses of soft mist inhaler (SMI)
trials, however, revealed a 51% increase in all-cause mortality for the intervention
group [RR1.51; 95% CI (1.08,2.11), I20%]. Sensitivity analysis did not change any
of the results. CONCLUSIONS: Overall, inhaled anticholinergics were not associ-
ated with an increased risk of all-cause mortality and might be considered as safe.
Analyses of tiotropium-SMI subgroup, however, suggested an increase inmortality
risk, necessitating more long term RCTs to assess its safety.
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OBJECTIVES: To assess the comorbid relationship between COPD and depression/
anxiety among Medicare beneficiaries. METHODS: Fee-for-service (FFS) part A, B
and D claims from the 5% Medicare Chronic Conditions Warehouse (CCW) from
January 1, 2006 to December 31, 2007were pooled to construct a prevalent cohort of
patients aged 65 with COPD (ICD-9-CM 491, 492, or 496). Depression/anxiety was
measured via health care services or prescription drug claims. Baseline character-
istics were assessed from January 1, 2006 to June 30, 2006 and patients were fol-
lowed from first depression/anxiety claim until December 31, 2007 for all-cause
and respiratory-related healthcare cost and utilization. COPD exacerbations were
defined as either moderate [outpatient encounter with an oral corticosteroid
and/or an antibiotic claim, or COPD-related emergency department visit] or severe
(COPD-related hospital admission). Prevalence estimates of co-occurring COPDand
depression/anxiety were estimated. Generalized linear models with a gamma dis-
tribution and a log link were used to model total and respiratory-related annual
adjusted costs. Risk of amoderate, severe, or any exacerbationwas estimated using
logistic regressionmodels.RESULTS:Of the 1,591,413 enrolleesmeeting the criteria
of 12 months of FFS coverage, 137,275 were selected from the 5% CCW sample.
Depression/anxiety was found in 55% (75,375) of the cohort. After controlling for
sex, age, region, race, Charlson comorbidity score, and use of COPD-related medi-
cations in the baseline period, enrolleeswith depression/ anxiety had a 51% greater
risk of having a moderate exacerbation (OR 1.51, 95% CI 1.39-1.64) and 78% higher
risk of a severe exacerbation (OR 1.78, 95% CI 1.50-2.11). After adjustment, depres-
sion/anxiety was associated with $50,622 (95% CI 49,007-52,237) greater annual
total cost and $35,789 annual respiratory-related costs (95% CI 34,328-37,251).
CONCLUSIONS: Clinical and economic costs associated with depression/anxiety
among COPD Medicare FFS enrollees are substantial. More emphasis should be
placed on identification and treatment of depression/anxiety among this popula-
tion.
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OBJECTIVES: Depression is a common co-morbid condition in patients with
asthma and is associatedwithworsening of asthmaoutcomes. Increased symptom
burden increases health care utilization and may lead to increased health care
expenditures. The purpose of this study was to assess whether individuals with
asthma and co-morbid depressive disorders have higher health care expenditures
compared to individuals with asthma alone. METHODS: Two cohorts of patients
with or without co-morbid depression were formed from the 2009 Medical Expen-
diture Panel Survey (MEPS). Propensity score (PS) matching technique was used to
balance the cohorts on various parameters such as demographic information, in-
surance status. Patients with co-morbid depression were matched to patients
without co-morbid depression on the logit of propensity score using calipers of
width equal to 0.2 of the standard deviation of the logit of the propensity score.
Difference in the health care expenditure of patients with co-morbid depression
and those with asthma alone was calculated using the independent sample t test.
RESULTS: Of the total 29,282 survey respondents, 8.1% (n2,375) were asthmatic.
The prevalence of co-morbid depression in asthma patients (12.33%, n293) was
comparatively higher than the prevalence of depression (7.55%, n2,212) in the rest
of the survey population. The total average health care expenditure of asthmatic
patients with co-morbid depression ($15,427.33 ) was significantly higher than the
health care expenditure of matched asthma patients without depression
($10,243.80) (p 0.02). CONCLUSIONS: Asthmatic individuals with co-morbid de-
pression have higher health care expenditures compared to individuals with
asthma alone, even after adjusting for differences in demographic information and
insurance status. Further research is required to investigate the causal relationship
between increase in health care expenditure of asthmatic patients with co-morbid
depression.
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OBJECTIVES: This study evaluated the impact of omalizumab on emergency-de-
partment (ED) visits, hospitalizations and corticosteroid use among uncontrolled
asthma patients using high-dose inhaled corticosteroids (ICS) prior to initiating
omalizumab. METHODS: Health insurance claims from the MarketScan database
(2002Q1-2009Q1) were analyzed. Patients with 12 months of continuous insur-
ance coverage prior to and after the first omalizumab dispensing, 8 weeks of
high-dose ICS use, 8 weeks of long-acting beta2-agonist (LABA) use, and uncon-
trolled asthma at baseline were included. A retrospective analysis was conducted
to quantify the impact of omalizumab on resource use by comparing ED visits,
hospitalizations, and corticosteroid use one year before and after omalizumab
initiation. A one-year period was chosen to cover any potential seasonality
impacts. RESULTS: A total of 644 patients (mean age: 49.9; female: 59.2%) formed
the study population. Omalizumab was associated with a 48.6% reduction in the
proportion of patients with 1 asthma-related ED visits (pre vs. post-omalizumab
period: 21.4% vs. 11.0%, P0.001) and 40.8% reduction in asthma-related hospital-
izations (25.0% vs. 14.8%, respectively, P0.001). Compared to the pre-omalizumab
period, the use of ICS decreased significantly after omalizumab initiation (7.8 vs. 6.5
dispensings, P0.001; 41.9% of patients had a reduction in ICS use). A similar re-
duction in oral corticosteroid use was observed (5.0 vs. 3.6 dispensings, P.001;
53.3% of patients had a reduction in oral corticosteroid use). CONCLUSIONS: The
results of the current study showed that omalizumab treatment initiation was
associatedwith statistically significant reductions in EDvisits, hospitalizations and
corticosteroid use.
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OBJECTIVES: Utility based health outcome measures add more meaning to eco-
nomic outcome analysis involving health related quality of life (HRQoL) assess-
ments. The purpose of this study was to compare the cost effectiveness and utility
analysis of inhaled corticosteroids like fluticasone, beclomethasone and budes-
onide at equipotent doses in asthma patients with patients’ perspective.
METHODS: A prospective study was conducted on 187 asthmatics of GINA (Global
Initiative on Asthma) grade-II, III and IV severity who received equipotent doses of
either beclomethasone dipropionate (BDP), budesonide (BUD) or fluticasone (FP) for
six months duration. As the cost analysis focused on patients’ perspective, the
meanmonthly cost on the Inhaled Corticosteroid (ICS) treatments were calculated
based on both direct and indirect cost incurred. The percentage satisfaction was
recorded on a 10cm Visual Analogue Scale (VAS) and QoL assessment performed
using Saint Georges Respiratory Questionnaire (SGRQ). Treatment efficacy was
compared using improvement in FEV1 (Forced Expiratory Volume in 1 second).
Statistical analysis was performed using SPSS version-13.0. RESULTS: The overall
QoL interpretation by VAS and SGRQ-total scores were checked for its association
and found to be significantly correlating (r -0.79, p0.01). Themean cost per unit
satisfaction (cost utility value) considering QoL improvement and the average cost
effective ratio (ACER) were assessed for ICS treatments. Cost per unit satisfaction
with ICS was comparable (p0.05) between treatments, where BUD group showed
value in Indian Rupees 7.92/-, FP-7.81/- and BDP-7.66/-. ACER with individual ther-
apy also showed similar results between the ICS groups (BUD-0.93, FP-0.95, and
BDP-1.06). CONCLUSIONS: The study observed no significant difference between
ICS groups with respect to cost utility value. At equipotent doses fluticasone, how-
ever, is similar to that of budesonide but more cost effective than beclomethasone
dipropionate.
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OBJECTIVES: To examine whether use of statins reduces the risk of hospitalization
for a chronic obstructive pulmonary disease (COPD) exacerbation. METHODS: A
nested case-control study of all patients diagnosed with COPD (ICD-9-CM codes
491-492, 496) and receiving COPDmedications were conducted between January 1,
2000 andDecember 31, 2008, using the TaiwanNational Health Insurance Research
Databases. Cases were defined as those admitted for COPD exacerbations. Each
case was matched to four randomly-selected controls by age, sex and cohort entry
date. Any use of statins was evaluated during the follow-up period and further
categorized by recency, average daily dose and duration of statin use. Conditional
logistic regressions were employed to estimate odds ratios (ORs). RESULTS: The
study cohort comprised 14,316 COPD patients, from which 1620 cases with COPD
exacerbations and 6432 matched controls were identified. Any use of statins was
associated with a 33% decreased risk of hospitalization for COPD exacerbation
(adjusted OR, 0.67; 95% CI, 0.54-0.83). A significant reduction in the risk for COPD
exacerbation was only observed among current users of statins (180 days; ad-
justed OR, 0.60; 95% CI, 0.45-0.81). Statins prescribed at an average daily dose of
0.45-0.60 defineddaily dose (DDD, adjustedOR, 0.52; 95%CI, 0.34-0.80) or0.60DDD
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